Treatment of Primary Myelofibrosis with Anaemia and Adequate Serum Erythropoietin (≥500 mU/mL)

This protocol addresses the management of primary myelofibrosis in patients who present with anaemia and a serum erythropoietin level classified as adequate — specifically ≥500 mU/mL. The erythropoietin level is a key determinant of the initial treatment path in this setting.

Clinical Scenario

Patients have myelofibrosis with anaemia and an adequate serum erythropoietin level (≥500 mU/mL). Serum EPO level is used to guide treatment selection: routine practice suggests that those with EPO levels below 500 mU/mL likely merit an erythropoiesis-stimulating agent (ESA) trial for 12 weeks. This protocol applies specifically to the distinct population with adequate EPO.

Treatment Approach (Partial)

Initial management focuses on identifying and correcting reversible contributors to the anaemia before considering further escalation. The complete protocol specifies the deficiencies to address, the haematological complication to evaluate, and the criteria that guide next steps.

Full regimen details, decision criteria, and sequencing are available in the structured protocol below.

Instant Access to Structured Evidence-Based Regimens

References

Serum EPO level — Adequate — However routine practice would suggest that those with EPO levels <500 mU/mL likely merit an ESA trial for 12 weeks.
Initial management is to correct any reversible haematinic deficiencies and to address any evidence of autoimmune haemolysis, albeit this is uncommon.
Initial management of anaemia should address any deficiencies of iron, folate or vitamin B12 and/or autoimmune haemolysis (Grade 1B).

View source ↗